Regulation of adiponectin secretion in human subcutaneous and omental adipose tissue: effects of pioglitazone and endothelin-1: a pilot study.
OBJECTIVE
The study was designed to test the effect of anti-diabetic agent pioglitazone and Endothelin-1 (ET-1) on adiponectin secretion from human adipose tissue in depot dependent manner.


METHODS
Subcutaneous adipose tissue (SAT) and omental adipose tissues (OAT) were obtained from 19 subjects, including 6 non-obese controls, 7 obese and 6 obese T2DM patients. Adipose tissue was treated with pioglitazone and ET1. Adiponectin secreted into the culture medium after treatment at different time interval (0, 24, 48, 96 hours) was determined by ELISA and normalized for cellular DNA content.


RESULTS
Basal adiponectin secretion from both the depots significantly associated with serum adiponectin, BMI, waist and HOMA-IR. Though no depot-specific difference was found in adiponectin secretion from SAT and OAT in our population, significant reduction in adiponectin secretion was observed in SAT of obese and T2DM patients compared to controls. Responsiveness to pioglitazone treatment was more in SAT, while ET1 inhibits adiponectin secretion in OAT.


CONCLUSIONS
These data suggest that, SAT, appears to be major contributor to regulation of adiponectin in circulation. Pioglitazone stimulate adiponectin secretion in SAT compared to OAT in diabetic patients while ET-1 inhibiting adiponectin secretion in OAT of diabetic patients. We need to focus on mechanism underlying these regulatory agents mediated stimulation or inhibition of adiponectin secretion in human adipose tissue.
Sir Hurkisondas Nurrotumdas Medical Research Society, Mumbai, India.
Sujata R
SR
Mahadik
Jaslok Hospital and Research Centre, Mumbai, India.
Ramchandra D
RD
Lele
Sir Hurkisondas Nurrotumdas Medical Research Society, Mumbai, India.
Suresh D
SD
Mehtalia
Sir Hurkisondas Nurrotumdas Medical Research Society, Mumbai, India.
Sudha S
SS
Deo
Sir Hurkisondas Nurrotumdas Medical Research Society, Mumbai, India.
Vikram
V
Parikh
D052242:Adiponectin / Q000378:metabolism*; D000328:Adult; D000368:Aged; D003924:Diabetes Mellitus, Type 2 / Q000378:metabolism / Q000473:pathology / Q000601:surgery; D019332:Endothelin-1 / Q000494:pharmacology*; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D050152:Intra-Abdominal Fat / Q000187:drug effects* / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000378:metabolism / Q000473:pathology / Q000601:surgery; D009852:Omentum; D010865:Pilot Projects; D000077205:Pioglitazone; D050507:Subcutaneous Fat, Abdominal / Q000187:drug effects* / Q000378:metabolism; D045162:Thiazolidinediones / Q000494:pharmacology*; D046509:Tissue Culture Techniques
D052242:Adiponectin; D019332:Endothelin-1; D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000077205:Pioglitazone